A study looking at pazopanib for advanced kidney cancer (Pazo2)

Please note - this trial is no longer recruiting patients. We hope to add results when they are available.

Cancer type:

Kidney cancer
Renal cell carcinoma




Phase 2

This study is looking at pazopanib for people with advanced kidney cancer (renal cancer) that has not been treated yet. This trial is supported by Cancer Research UK.


More about this trial

Pazopanib is a type of biological therapy.  It is a cancer growth blocker. It stops signals that cancer cells use to divide and grow.

Doctors can treat advanced kidney cancer with pazopanib. They usually use it to treat people who have kidney cancer that is not causing them too many problems.

In this study doctors want to find out if pazopanib can help people who have a range of problems caused by their kidney cancer that affect their well being and quality of life Open a glossary item.

The aims of this study are to find out

  • If pazopanib can help people who have kidney cancer that affects their well being and quality of life
  • About the side effects

Who can enter

You may be able to enter this trial if you

  • Have kidney cancer (renal cell cancer) that is clear cell type
  • Have kidney cancer that cannot be removed with surgery
  • Have kidney cancer that can be measured on CT scan
  • Are well enough to be up and about more than half the day and can look after yourself, but are not well enough to work (performance status of 2)
  • Have satisfactory blood and urine test results
  • Are willing to use reliable contraception during treatment and for 4 weeks afterwards if there is any chance that you or your partner could become pregnant
  • Are at least 18 years old

You cannot enter this trial if you

  • Have had treatment for your kidney cancer in the past that reached the whole of your body (systemic treatment Open a glossary item)
  • Have had major surgery in the last 4 weeks
  • Have a wound that has not healed, or a bone fracture that has not healed
  • Have had radiotherapy in the last 2 weeks
  • Have cancer that has spread to your brain
  • Have certain heart problems
  • Have had any other cancer, apart from cancer in situ Open a glossary item that was successfully treated at least 5 years ago
  • Have high blood pressure that cannot be controlled with medication
  • Are taking any medication that blocks the CYP3A4 enzyme – you can check this with your doctor
  • Have an infection that cannot be controlled with medication, or any other condition that would make it unsafe for you to take part in this trial
  • Have problems with digestion and cannot absorb tablets
  • Have had problems with blood clots in the last 6 months, unless they are in your leg (DVT) and you are having treatment
  • Have any problems with uncontrolled bleeding
  • Are allergic to pazopanib or similar medication
  • Are pregnant or breastfeeding

Trial design

This study will recruit 75 people from the UK. Everybody taking part has pazopanib tablets daily.

You take pazopanib for as long as it is helping you.

If you agree to take part in this study, the researchers will ask for a sample of tissue taken when you had surgery to diagnose your cancer. They will also ask for extra blood samples for research. If you do not wish to give tissue or blood samples for this study, you don’t have to. You can still take part in the study.

Hospital visits

You will see the doctors and have some tests before you start treatment. The tests include

  • Blood tests
  • Physical examination
  • Heart trace (ECG Open a glossary item)
  • Urine tests
  • CT scan
  • Bone scan (if needed)

You see the doctors and have blood and urine tests frequently while you are having treatment. You have a CT scan

  • Every 6 weeks for 12 weeks
  • Then every 8 weeks

When you stop treatment you see the doctors and have blood and urine tests 4 weeks later. The doctors will then see you every 3 months.

Side effects

The most common side effects of pazopanib are

We have more information about pazopanib in our cancer drugs section.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Emilio Porfiri

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham

Other information

This is Cancer Research UK trial number CRUKE/11/016.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Cara took part in a clinical trial

A picture of Cara

"I am glad that taking part in a trial might help others on their own cancer journey.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think